www.BuyersGuideChem.de contiene fabricantes y proveedores de productos químicos, sustancias activas farmacéuticas, APIs y otras sustancias químicas
Hydranal Logo
Bienvenido Acerca de BGC Condiciones de utilización Banners publicitarios Pie de imprenta
BGC > Buscar Producto > PSI-6130 derivative | 817204-32-3
english deutsch español

Proveedores de CAS

817204-32-3

Identificación

CAS   817204-32-3 
Formula   C31H26FN3O7 

13 Proveedores registrados

Simagchem Corporation P.R.China
rd (2'R)-N-Benzoyl-2'-deoxy-2'-fluoro-2'-methylcytidine 3',5'-dibenzoate  
Dayang Chem (Hangzhou) Co.,Ltd. P.R.China
rd (2'R)-N-Benzoyl-2'-deoxy-2'-fluoro-2'-methylcytidine 3',5'-dibenzoate  
Xingrui Industry Co., Limited P.R.China
rd PSI-6130 derivative  
Leap Chem Co., Ltd P.R.China
rd PSI-6130 derivative   CD details
Guangzhou Topwork Chemical Co., Ltd. P.R.China
rd Sofosbuvir intermediate 2  
Hangzhou Verychem Science & Technology Co., Ltd. P.R.China
rd Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)-  
Hangzhou Zhongqi Chem Co., Ltd P.R.China
rd Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)-  
Nantong Xindao Biotech Ltd P.R.China
rd Cytidine, N-benzoyl-2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-dibenzoate, (2'R)-  
NewCan Biotech Limited P.R.China
rd N-Benzoyl-2'-deoxy-2'-fluoro-2'-methyl-,3',5'-dibenzoate,(2'r)cytidine  
Shandong SanYoung Industry Co., Ltd P.R.China
rd (2'R)-N-Benzoyl-2'-deoxy-2'-fluoro-2'-methylcytidine 3',5'-dibenzoate   CD details
Allfluoro Pharmaceutical Co. Ltd. P.R.China
rd (2'R)-N-Benzoyl-2'-deoxy-2'-fluoro-2'-methylcytidine 3',5'-dibenzoate   CD details
Ambeed, Inc. USA
rd (2R,3R,4R,5R)-5-(4-Benzamido-2-oxopyrimidin-1(2H)-yl)-2-((benzoyloxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate   CD details
BLD Pharmatech Ltd P.R.China
rd (2R,3R,4R,5R)-5-(4-Benzamido-2-oxopyrimidin-1(2H)-yl)-2-((benzoyloxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate   CD details
Información detallada sobre los proveedores de PSI-6130 derivative
Copyright © 1996-2024 Netvertise Inc. Todos los derechos reservados.